Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo

PHASE3CompletedINTERVENTIONAL
Enrollment

736

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

February 28, 2019

Study Completion Date

April 30, 2019

Conditions
Axial SpondyloarthrithisAnkylosing Spondylitis
Interventions
BIOLOGICAL

Certolizumab Pegol

"* Active substance: Certolizumab Pegol~* Pharmaceutical form: Prefilled syringe~* Concentration: 200 mg / ml~* Route of Administration: Subcutaneous injection"

OTHER

Placebo

"* Active substance: Placebo~* Pharmaceutical form: Prefilled syringe~* Concentration: 0.9 % Saline~* Route of Administration: Subcutaneous injection"

Trial Locations (108)

16635

As0005 2311, Duncansville

21742

As0005 2321, Hagerstown

33511

As0005 2302, Brandon

38305

As0005 2315, Jackson

58701

As0005 2312, Minot

73101

As0005 2323, Oklahoma City

75231

As0005 2318, Dallas

78731

As0005 2303, Austin

80230

As0005 2308, Denver

85037

As0005 2314, Phoenix

85202

As0005 2316, Mesa

85304

As0005 2313, Glendale

85351

As0005 2317, Sun City

91786

As0005 2305, Upland

92260

As0005 2307, Palm Desert

94143

As0005 2310, San Francisco

Unknown

As0005 1006, Genk

As0005 1001, Ghent

As0005 1004, Merksem

As0005 1003, Mons

As0005 1109, Pleven

As0005 1103, Plovdiv

As0005 1106, Plovdiv

As0005 1111, Rousse

As0005 1110, Sevlievo

As0005 1101, Sofia

As0005 1108, Sofia

As0005 1308, Brno

As0005 1309, Bruntál

As0005 1301, Kladno

As0005 1307, Ostrava

As0005 1303, Pardubice

As0005 1302, Prague

As0005 1305, Prague

As0005 1306, Prague

As0005 1310, Prague

As0005 1311, Prague

As0005 1314, Prague

As0005 1313, Uherské Hradiště

As0005 1304, Zlín

As0005 1504, Montpellier

As0005 1505, Orléans

As0005 1501, Paris

As0005 1503, Tours

As0005 1406, Berlin

As0005 1408, Berlin

As0005 1410, Berlin

As0005 1412, Berlin

As0005 1413, Bochum

As0005 1407, Cologne

As0005 1405, Erlangen

As0005 1404, Frankfurt am Main

As0005 1402, Hamburg

As0006 1409, Herne

As0005 1403, Leipzig

As0005 1705, Budapest

As0005 1710, Budapest

As0005 1704, Debrecen

As0005 1706, Miskolc

As0005 1711, Nyíregyháza

As0005 1707, Szeged

As0005 1702, Szentes

As0005 1703, Szombathely

As0005 1701, Veszprém

As0005 2502, Amsterdam

As0005 2503, Rotterdam

As0005 2501, Sneek

As0005 1806, Bialystok

As0005 1805, Bydgoszcz

As0005 1801, Elblag

As0005 1802, Elblag

As0005 1812, Krakow

As0005 1808, Lodz

As0005 1814, Lodz

As0005 1803, Lublin

As0005 1816, Ostrowiec Świętokrzyski

As0005 1809, Poznan

As0005 1813, Poznan

As0005 1807, Torun

As0005 1804, Warsaw

As0005 1811, Warsaw

As0005 1815, Warsaw

As0005 1912, Brasov

As0005 1904, Brăila

As0005 1902, Bucharest

As0005 1903, Bucharest

As0005 1913, Bucharest

As0005 1907, Cluj-Napoca

As0005 1910, Iași

As0005 1911, Târgu Mureş

As0005 2403, Córdoba

As0005 2404, Getafe

As0005 2401, Madrid

As0005 2402, Seville

As0005 2205, Kaohsiung City

As0005 2201, Taichung

As0005 2202, Taichung

As0005 2203, Taipei

As0005 2204, Taipei

As0005 2206, Taipei

As0005 2101, Ankara

As0005 2103, Edirne

As0005 2102, Gaziantep

As0005 2105, Istanbul

As0005 2106, Istanbul

As0005 2104, Izmir

As0005 1603, Leeds

As0005 1601, Norwich

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

UCB BIOSCIENCES GmbH

INDUSTRY